A former employee of Swiss pharmaceutical giant Novartis AG’s Japanese unit has been found not guilty of exaggerating advertising claims for the blood pressure-lowering drug Diovan. Besides clearing 66-year-old Nobuo Shirahashi on Thursday of violating a pharmaceutical affairs law that bans fraudulent and exaggerated ...
The health ministry will censure a Japanese unit of Swiss pharmaceutical giant Novartis AG for failing to report serious side effects from some of its drugs within a certain period of time, sources close to the matter said Wednesday. The Ministry of Health, Labor ...
Gene therapy for deafness is moving closer to reality, with new research on Wednesday showing the technique for fixing faulty DNA can improve responses in mice with genetic hearing loss. Separately, a clinical trial backed by Novartis is under way to help a different ...
Some 400,000 psoriasis sufferers can look forward to relief after Japan becomes the first country to permit sales of a promising new treatment for the skin malady.
Novartis Pharma admits it failed to report at least 2,579 cases of serious side effects to the health ministry even though its employees were aware of the problems.
The Health, Labor and Welfare Ministry issued a business improvement order Thursday to Novartis Pharma K.K. for its failure to report serious side effects of its leukemia treatment drugs. The Tokyo-based unit of Swiss drug giant Novartis AG did not report serious side effects ...
Tokyo prosecutors charged Novartis Pharma K.K. and a former employee Tuesday with causing a medical research team to release data manipulated in favor of the firm’s drug for treating high blood pressure in 2011. The prosecutors also issued a fresh arrest warrant for the ...
A former employee of Novartis Pharma K.K. has been arrested for allegedly manipulating clinical study data for one of the company’s drugs.
Novartis Pharma K.K. failed to inform the government of at least 10 suspected cases of serious side effects involving its Tasigna leukemia drug, it was learned Friday. The Health, Labor and Welfare Ministry has opened an investigation into whether the Novartis unit broke the ...
Swiss pharmaceutical giant Novartis said Thursday it is replacing the top executives at its Japanese unit over allegations that the division hid the existence of serious potential side effects linked to leukemia treatments from regulators. David Epstein, head of the firm’s pharmaceutical division, told ...
The manipulation of clinical research data used to develop the blood pressure drug Diovan sold by Novartis Pharma K.K. has prompted a special squad of Tokyo prosecutors to search the Japanese unit of the Swiss drugmaker as well as the universities that conducted the ...
Tokyo prosecutors raided Novartis Pharma K.K. on Wednesday over its alleged use of exaggerated advertising for a blood pressure-lowering drug, following a criminal complaint filed by the health ministry last month. The ministry claimed that the ads for Diovan cited clinical study reports by ...
